Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + mFOLFOX6 in Metastatic Colorectal Cancer
NCT01289821Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2011
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in metastatic colorectal cancer (mCRC), sponsored by Bayer. Primary endpoint: Objective Response. Started Feb 2011; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01289821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01289821.